Skip to main content
Journal cover image

Sildenafil improves walk distance in idiopathic pulmonary fibrosis.

Publication ,  Journal Article
Collard, HR; Anstrom, KJ; Schwarz, MI; Zisman, DA
Published in: Chest
March 2007

Pulmonary hypertension is a common finding in patients with idiopathic pulmonary fibrosis (IPF), and is associated with increased morbidity and mortality. Therapy with sildenafil has been shown to decrease pulmonary vascular resistance in patients with pulmonary fibrosis and may improve functional status. Patients with IPF and documented pulmonary hypertension were followed up in an open-label study of sildenafil. The 6-min walk test distance (6MWD) was obtained before and after 3 months of sildenafil therapy. Fourteen patients were followed up in the study; 11 patients completed both 6-min walk tests. The mean improvement in walk distance was 49.0 m (90% confidence interval, 17.5 to 84.0 m). When all 14 patients were dichotomized into groups of "responders" (ie, >/= 20% improvement in 6MWD) or "nonresponders" (ie, < 20% change or unable to complete), 57% were classified as responders. Sildenafil is a promising and well-tolerated therapeutic agent for use in patients with IPF and pulmonary hypertension, and should be studied in a large, well-controlled trial.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Chest

DOI

ISSN

0012-3692

Publication Date

March 2007

Volume

131

Issue

3

Start / End Page

897 / 899

Location

United States

Related Subject Headings

  • Walking
  • Vasodilator Agents
  • Vascular Resistance
  • Sulfones
  • Sildenafil Citrate
  • Respiratory System
  • Purines
  • Pulmonary Wedge Pressure
  • Pulmonary Fibrosis
  • Piperazines
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Collard, H. R., Anstrom, K. J., Schwarz, M. I., & Zisman, D. A. (2007). Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest, 131(3), 897–899. https://doi.org/10.1378/chest.06-2101
Collard, Harold R., Kevin J. Anstrom, Marvin I. Schwarz, and David A. Zisman. “Sildenafil improves walk distance in idiopathic pulmonary fibrosis.Chest 131, no. 3 (March 2007): 897–99. https://doi.org/10.1378/chest.06-2101.
Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007 Mar;131(3):897–9.
Collard, Harold R., et al. “Sildenafil improves walk distance in idiopathic pulmonary fibrosis.Chest, vol. 131, no. 3, Mar. 2007, pp. 897–99. Pubmed, doi:10.1378/chest.06-2101.
Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007 Mar;131(3):897–899.
Journal cover image

Published In

Chest

DOI

ISSN

0012-3692

Publication Date

March 2007

Volume

131

Issue

3

Start / End Page

897 / 899

Location

United States

Related Subject Headings

  • Walking
  • Vasodilator Agents
  • Vascular Resistance
  • Sulfones
  • Sildenafil Citrate
  • Respiratory System
  • Purines
  • Pulmonary Wedge Pressure
  • Pulmonary Fibrosis
  • Piperazines